Will Teva’s Fremanezumab Be Delayed due to Troubles at Celltrion?
Teva Pharmaceutical (TEVA) has a number of key specialty assets that are touted as key long-term growth drivers for the company. Fremanezumab, a drug used for the treatment of migraines in adults, is one such product in the company’s specialty asset portfolio. The drug was accepted for review by the FDA in December 2017 and by the EMA (European Medicines Agency) in February 2018.